Advocacy intelligence hub — real-time data for patient organizations
CUTISS AG — PHASE3
CUTISS AG — PHASE2
CUTISS AG — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
NexoBrid
(anacaulase-bcdb)Orphan drugstandardVericel Corporation
12.1 Mechanism of Action The mixture of enzymes in NEXOBRID dissolves burn wound eschar. The specific components responsible for this effect have not ...
StrataGraft
(allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat)Orphan drugstandardStratatech Corporation, a Mallinckrodt company
Browse all Partial deep dermal and full thickness burns news →
Sophie Böttcher, PD Dr. med.
University Children's Hospital, Zurich
Clemens Schiestl
University Children's Hospital, Zurich
View all Partial deep dermal and full thickness burns specialists →